Merck & Co., Inc. (MRK)
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with oncology pipeline and R&D focus, supports long-term growth despite near-term Gardasil sales decline. Heavy reliance on Keytruda, integration of new drugs, Gardasil sales volatility, and dependence on successful clinical trials could pressure revenue if outcomes disappoint.
EMA committee recommends approval for injectable version of Merck's Keytruda
The European Medicines Agency's committee has recommended the approval for a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker said on Friday.
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging business environment was hurting the sector.
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
Merck: Buy The Weakness
Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results, but loss of exclusivity looms in three years. Merck's pipeline and Verona acquisition position it to offset Keytruda revenue loss, with $50B+ mid-2030s opportunity projected.
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
